1.
Antimicrob Agents Chemother
; 38(7): 1644-6, 1994 Jul.
Article
in English
| MEDLINE
| ID: mdl-7979299
ABSTRACT
Nineteen young human immunodeficiency virus-infected patients were randomized to receive 400 mg of oral diethyldithiocarbamate (DTC) per m2 or placebo weekly for 12 weeks. Changes in blood CD4+ lymphocytes were not significantly different between groups. However, neutrophil, monocyte, and platelet counts consistently decreased during DTC treatment, suggesting DTC-mediated myelosuppression.